Effects of berberine on the secretion of cytokines and expression of genes involved in cell cycle regulation in THP-1 monocytic cell line

Authors

1 Student Research Committee and Department of Molecular Medicine, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran

2 Infectious Diseases Research Center and Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran

3 Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Abstract

Objective(s): Current acute myeloid leukemia (AML) therapeutic strategies have irreversible side-effects. Berberine (BBR) is an isoquinoline alkaloid, which has been known as an aryl hydrocarbon receptor (AhR) ligand. AhR is a cytoplasmic receptor, which is involved in the regulation of cellular and immune responses. Here, we investigated the expression profile of genes involved in the cell cycle and different cytokines upon BBR-mediated AhR activation on AML THP-1 cell line.
Materials and Methods: THP-1 cells and normal monocytes were treated with different concentrations of BBR (10 μM, 25 μM, 50 μM, and 100 μM) for 24 and 48 hr. The cell viability was measured by MTT assay. Real-time RT-PCR was conducted to evaluate the expression of AhR, cytochrome P450 1A1 (CYP1A1), interleukin 1 beta (IL1β), p21, p27, cyclin-dependent kinase 2 (CDK2) and p53. Cellular expression of AhR was also assessed using immunofluorescence method. ELISA was used to determine the level of IL-10 and IL-12 cytokines.
Results: BBR inhibits the proliferation of THP-1 cells in a dose- and time-dependent manner with minimal toxicity on normal monocytes. Phorbol 12-myristate 13-acetate (PMA) treatment increased the cellular expression of AhR. The AhR target genes (CYP1A1, IL1β) were overexpressed upon BBR treatment. BBR downregulated Cdk2 and upregulated p21, p27 and p53 genes in THP-1 cells. IL-10 was significantly increased upon BBR treatment, while IL-12 was not significantly changed in all combinations.
Conclusion: BBR could be introduced as an effective chemotherapeutic agent against AML by giving rise to the expression of CDK inhibitors and anti-inflammatory cytokines and downregulation of CDK2.

Keywords


1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Eng J Med 2015; 373:1136-1152.

2. Yaswen P, MacKenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J, et al. Therapeutic targeting of replicative immortality. Semin Cancer Biol 2015; 35:s104-128.

3. Yao J, Kong W, Jiang J. Learning from berberine: Treating chronic diseases through multiple targets. Sci China Life Sci 2015; 58:854-859.

4. Shahneh FZ, Baradaran B, Orangi M, Zamani F. In vitro cytotoxic activity of four plants used in Persian traditional medicine. Adv Pharm Bull 2013; 3:453-455.

5. Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med 2014; 12: 289264.

6. Ahmadiankia N, Moghaddam HK, Mishan MA, Bahrami AR, Naderi-Meshkin H, Bidkhori HR, et al. Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors. Iran J Basic Med Sci 2016; 19:125-131.

7. Barzegar E, Fouladdel S, Komeili Movahhed T, Atashpour S, Ghahremani MH, Ostad SN, et al. Effects of berberine on proliferation, cell cycle distribution and apoptosis of human breast cancer T47D and MCF7 cell lines. Iran J Basic Med Sci 2015; 18:334-342.

8. Lu JJ, Fu L, Tang Z, Zhang C, Qin L, Wang J, et al. Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. Oncotarget 2016; 7:2985.

9. Zhu T, Li LL, Xiao GF, Luo QZ, Liu QZ, Yao KT, et al. Berberine increases doxorubicin sensitivity by suppressing STAT3 in lung cancer. Am J Chin Med 2015; 43:1487-1502.

10. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett 2013; 332:304-312.

11. Vrzal R, Zdařilová A, Ulrichová J, Bláha L, Giesy JP, Dvořák Z. Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: Biphasic effect on CYP1A1. Biochem Pharmacol 2005; 70:925-936.

12. Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. Curr Drug Metab 2011; 12:198-212.

13. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279:23847-23850.

14. Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer 2014; 14:801-814.

15. Faust D, Kletting S, Ueberham E, Dietrich C. Aryl hydrocarbon receptor-dependent cell cycle arrest in isolated mouse oval cells. Toxicol Lett 2013; 223:73-80.

16. Stockinger B, Meglio PD, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 2014; 32:403-432.

17. Safe S, Lee SO, Jin UH. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci 2013; 135:1-16.

18. Nakashima KI, Tanabe H, Fujii-Kuriyama Y, Hayashi H, Inoue M. Atranorin and lecanoric acid antagonize TCDD-induced xenobiotic response element-driven activity, but not xenobiotic response element-independent activity. J Nat Med 2016;70: 476-482.

19. Fritz WA, Lin TM, Cardiff RD, Peterson RE. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2006; 28:497-505.

20. Fritz WA, Lin TM, Safe S, Moore RW, Peterson RE. The selective aryl hydrocarbon receptor modulator 6-methyl-1, 3, 8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. Biochem Pharmacol 2009; 77:1151-1160.

21. Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 2010; 70:212-220.

22. Hahn ME, Allan LL, Sherr DH. Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor. Biochem Pharmacol 2009; 77:485-497.

23. Rowland LK, McLean LS, Campbell P, Watkins CN, Zylstra D, Amis LH, et al. Aryl hydrocarbon receptor agonist 5F 203 induces oxidative stress triggering DNA damage and cytoglobin up-regulation in human breast cancer cells. Cancer Res 2015; 75:2565-2565.

24. O'donnell E, Koch D, Bisson W, Jang H, Kolluri S. The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death Dis 2014; 5:e1038.

25. McMahon G, Taylor AE, Smith GD, Munafò MR. Phenotype refinement strengthens the association of AHR and CYP1A1 genotype with caffeine consumption. PloS One 2014; 9:e103448.

26. John K, Hughes J, Lahoti T, Kelly W, Gary P. Growth factors regulated by the aryl hydrocarbon receptor in highly metastatic head and neck squamous cell carcinoma cell lines. Cancer Res 2013; 73:4093-4093.

27. Habijanic J, Berovic M, Boh B, Plankl M, Wraber B. Submerged cultivation of Ganoderma lucidum and the effects of its polysaccharides on the production of human cytokines TNF-α, IL-12, IFN-γ, IL-2, IL-4, IL-10 and IL-17. N Biotechnol 2015; 32:85-95.

28. Tane S, Ikenishi A, Okayama H, Iwamoto N, Nakayama KI, Takeuchi T. CDK inhibitors, p21 Cip1 and p27 Kip1, participate in cell cycle exit of mammalian cardiomyocytes. Biochem Biophs Res Commun 2014; 443:1105-1109.

29. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of  macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PloS One 2010; 5:e8668.

30. Saghaeian-Jazi M, Mohammadi S, Sedighi S. Culture and differentiation of monocyte derived macrophages using human serum: an optimized method. Zahedan J Res Med Sci 2016; 18:e7362.

31. Yazdani Y, Roohi A, Khoshnoodi J, Shokri F. Development of a sensitive enzyme-linked immunosorbent assay for detection of hepatitis B surface antigen using novel monoclonal antibodies. Avicenna J Med Biotechnol 2010; 2:207-214.

32. Yazdani Y, Sadeghi H, Alimohammadian M, Andalib A, Moazen F, Rezaei A. Expression of an innate immune element (mouse hepcidin-1) in baculovirus expression system and the comparison of its function with synthetic human hepcidin-25. Iran J Pharm Res 2011; 10:559-568.

33. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 2006; 5:296-308.

34. Sun X, Zhang X, Hu H, Lu Y, Chen J, Yasuda K, et al. Berberine inhibits hepatic stellate cell proliferation and prevents experimental liver fibrosis. Biol Pharm Bull 2009; 32:1533-1537.

35. Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, et al. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 2009; 34:1221-1230.

36. Javaheri-Kermani M, Farazmandfar T, Ajami A, Yazdani Y. Impact of hepcidin antimicrobial peptide on iron overload in tuberculosis patients. Scand J Infect Dis 2014; 46:693-696.

37. Yazdani Y, Keyhanvar N, Kalhor HR, Rezaei A. Functional analyses of recombinant mouse hepcidin-1 in cell culture and animal model. Biotechnol Lett 2013; 35:1191-1197.

38. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004; 203:127-137.